PCSK9 Inhibitor [EPC]

105597 reported adverse events

Drugs of this class: ALIROCUMAB EVOLOCUMAB

These side effects are most commonly reported by patients taking drugs of the PCSK9 Inhibitor [EPC] class:

# Side effect Count
0 WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 10524
1 INJECTION SITE PAIN 8094
2 ACCIDENTAL EXPOSURE TO PRODUCT 7291
3 MYALGIA 5600
4 DRUG DOSE OMISSION 5255
5 BACK PAIN 4838
6 INJECTION SITE BRUISING 4038
7 ARTHRALGIA 3850
8 FATIGUE 3736
9 DEVICE DIFFICULT TO USE 3731
See all common reactions for PCSK9 Inhibitor [EPC]

Drugs of the PCSK9 Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 FRACTIONAL EXHALED NITRIC OXIDE INCREASED 29 0.6444
1 LOW DENSITY LIPOPROTEIN DECREASED 599 0.6163
2 TYPE IIA HYPERLIPIDAEMIA 54 0.3649
3 INCORRECT DISPOSAL OF PRODUCT 384 0.3174
4 LOW DENSITY LIPOPROTEIN ABNORMAL 106 0.2944
5 BLOOD CHOLESTEROL DECREASED 392 0.2928
6 LIPOPROTEIN (A) INCREASED 28 0.2154
7 DEVICE DIFFICULT TO USE 3731 0.1913
8 LOW DENSITY LIPOPROTEIN INCREASED 973 0.1791
9 ACCIDENTAL EXPOSURE TO PRODUCT 7291 0.1575
See all enriched reactions for PCSK9 Inhibitor [EPC]